A user reported transition to a triple blend of CJC-1295, Ipamorelin, and GHRP-2 at a dosage of 300mcg total. They noted the addition of GHRP-2 specifically to their existing secretagogue regimen.
A user reported transition to a triple blend of CJC-1295, Ipamorelin, and GHRP-2 at a dosage of 300mcg total. They noted the addition of GHRP-2 specifically to their existing secretagogue regimen.